Compare Stocks: DRUG, TRLV, XERS, and TRVI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DRUG Bright Minds Biosciences	$54.02 +5.7%	$61.30	$47.23 ▼ $123.75	$525.62M	-5.22	203,625 shs	59,400 shs
TRLV Trulieve Cannabis	$10.66 -1.5%	$11.17	$4.62 ▼ $13.28	$2.05B	N/A	962,328 shs	867,261 shs
TRVI Trevi Therapeutics	$13.35 +6.7%	$15.21	$9.82 ▼ $20.22	$1.90B	0.98	1.81 million shs	2.10 million shs
XERS Xeris Biopharma	$10.45 +2.4%	$9.15	$5.25 ▼ $11.41	$1.91B	0.53	2.02 million shs	1.52 million shs

The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DRUG Bright Minds Biosciences	-2.65%	-5.07%	-1.37%	-29.00%	-16.49%
TRLV Trulieve Cannabis	+3.62%	+4.88%	-11.87%	+29.27%	+1,077,299,900.00%
TRVI Trevi Therapeutics	-0.79%	+5.13%	-13.19%	-32.12%	+19.03%
XERS Xeris Biopharma	+0.10%	-6.76%	+12.20%	+23.91%	+10.86%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DRUG Bright Minds Biosciences	$54.02 +5.7%	$61.30	$47.23 ▼ $123.75	$525.62M	-5.22	203,625 shs	59,400 shs
TRLV Trulieve Cannabis	$10.66 -1.5%	$11.17	$4.62 ▼ $13.28	$2.05B	N/A	962,328 shs	867,261 shs
TRVI Trevi Therapeutics	$13.35 +6.7%	$15.21	$9.82 ▼ $20.22	$1.90B	0.98	1.81 million shs	2.10 million shs
XERS Xeris Biopharma	$10.45 +2.4%	$9.15	$5.25 ▼ $11.41	$1.91B	0.53	2.02 million shs	1.52 million shs

The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DRUG Bright Minds Biosciences	-2.65%	-5.07%	-1.37%	-29.00%	-16.49%
TRLV Trulieve Cannabis	+3.62%	+4.88%	-11.87%	+29.27%	+1,077,299,900.00%
TRVI Trevi Therapeutics	-0.79%	+5.13%	-13.19%	-32.12%	+19.03%
XERS Xeris Biopharma	+0.10%	-6.76%	+12.20%	+23.91%	+10.86%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DRUG Bright Minds Biosciences	2.91	Moderate Buy	$144.71	167.89% Upside
TRLV Trulieve Cannabis	2.00	Hold	$15.00	40.78% Upside
TRVI Trevi Therapeutics	2.92	Moderate Buy	$27.08	102.87% Upside
XERS Xeris Biopharma	2.43	Hold	$13.20	26.32% Upside

Current Analyst Ratings Breakdown

Latest DRUG, TRLV, XERS, and TRVI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/23/2026	TRLV Trulieve Cannabis	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$15.00
10/15/2026	TRVI Trevi Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	DRUG Bright Minds Biosciences	Wolfe Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$150.00
10/7/2026	TRVI Trevi Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
10/6/2026	XERS Xeris Biopharma	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$12.00 ➝ $14.00
9/28/2026	DRUG Bright Minds Biosciences	Lifesci Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/25/2026	TRVI Trevi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
9/15/2026	DRUG Bright Minds Biosciences	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
9/11/2026	TRLV Trulieve Cannabis	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/10/2026	XERS Xeris Biopharma	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$12.00 ➝ $16.00
8/20/2026	DRUG Bright Minds Biosciences	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Market Perform

(Data available from 10/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$8.33 per share	N/A
TRLV Trulieve Cannabis	$1.14B	1.80	N/A	N/A	N/A	∞
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.43 per share	N/A
XERS Xeris Biopharma	$335.41M	5.68	$0.10 per share	101.83	$0.08 per share	130.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DRUG Bright Minds Biosciences	-$8.74M	-$2.08	N/A	N/A	N/A	N/A	-12.46%	-12.30%	12/22/2026 (Estimated)
TRLV Trulieve Cannabis	-$116.38M	$0.11	96.86	18.69	N/A	-41.55%	-4.24%	-1.72%	N/A
TRVI Trevi Therapeutics	-$42.76M	-$0.34	N/A	N/A	N/A	N/A	-23.59%	-22.64%	11/12/2026 (Estimated)
XERS Xeris Biopharma	$550K	-$0.11	N/A	34.83	N/A	-5.12%	338.21%	3.50%	11/5/2026 (Estimated)

Latest DRUG, TRLV, XERS, and TRVI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	TRVI Trevi Therapeutics	-$0.1317	N/A	N/A	N/A	N/A	N/A
11/5/2026	Q3 2026	XERS Xeris Biopharma	$0.0317	N/A	N/A	N/A	$101.68 million	N/A
8/14/2026	Q3 2026	DRUG Bright Minds Biosciences	-$1.2230	-$0.17	+$1.0530	-$0.17	N/A	N/A
8/7/2026	Q2 2026	TRLV Trulieve Cannabis	$0.06	$0.11	+$0.05	-$2.10	$268.82 million	$271.00 million
8/6/2026	Q2 2026	TRVI Trevi Therapeutics	-$0.1095	-$0.11	-$0.0005	-$0.11	N/A	N/A
8/6/2026	Q2 2026	XERS Xeris Biopharma	$0.0121	-$0.18	-$0.1921	-$0.18	$90.13 million	$92.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
TRLV Trulieve Cannabis	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DRUG Bright Minds Biosciences	N/A	122.00	122.00
TRLV Trulieve Cannabis	0.45	5.94	3.98
TRVI Trevi Therapeutics	N/A	37.28	37.28
XERS Xeris Biopharma	17.00	1.45	1.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DRUG Bright Minds Biosciences	40.52%
TRLV Trulieve Cannabis	N/A
TRVI Trevi Therapeutics	95.76%
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
DRUG Bright Minds Biosciences	42.66%
TRLV Trulieve Cannabis	3.79%
TRVI Trevi Therapeutics	15.39%
XERS Xeris Biopharma	4.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DRUG Bright Minds Biosciences	25	9.73 million	5.58 million	Optionable
TRLV Trulieve Cannabis	5,000	192.57 million	185.27 million	Optionable
TRVI Trevi Therapeutics	34	142.48 million	120.55 million	Optionable
XERS Xeris Biopharma	435	182.32 million	174.39 million	Optionable

DRUG, TRLV, XERS, and TRVI Headlines

Recent News About These Companies

Xeris Biopharma Holdings Inc (XERS) Stock Down 6.1% but Still Overvalued -- GF Score: 66/100

October 23, 2026 | gurufocus.com

Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

October 22, 2026 | businesswire.com

Xeris presents endocrine data for Xeris Biopharma stock

October 20, 2026 | ad-hoc-news.deA

Xeris Biopharma (NASDAQ:XERS) Reaches New 52-Week High - Here's Why

October 20, 2026 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Stock Jumps 6.8% - Here's What Happened

October 19, 2026 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Has Average Target Price of $13.20 According to Brokerages

October 16, 2026 | americanbankingnews.com

Xeris Biopharma Holdings, Inc. (XERS) - What Are Researchers Thinking About This Stock?

October 16, 2026 | marketbeat.com

Xeris Biopharma Holdings, Inc. Announces Clinical and Scientific Data Presentations in Support of Gvoke, Recorlev, and Investigational Xp-8121 Program At Scientific Meetings

October 16, 2026 | marketscreener.comM

Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings

October 16, 2026 | finance.yahoo.com

1,060,000 Shares of Xeris Biopharma Holdings, Inc. $XERS Bought by Vilga Financial Planning LLC

October 9, 2026 | marketbeat.com

Barclays raised Xeris Biopharma stock target to USD 14.00

October 8, 2026 | ad-hoc-news.deA

Why Xeris Biopharma Holdings (XERS) Is Up 5.8% After Raising 2026 Revenue Guidance And Retiring Debt

October 8, 2026 | finance.yahoo.com

Xeris Biopharma (NASDAQ:XERS) Shares Climb 9.2% - Still a Buy?

October 5, 2026 | marketbeat.com

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - October 2, 2026

October 5, 2026 | biospace.comB

Xeris Biopharma (NASDAQ:XERS) Insider Steven Pieper Sells 5,000 Shares of Stock

October 3, 2026 | insidertrades.com

Xeris Biopharma (NASDAQ:XERS) Stock: Insider Steven Pieper Sells 5,000 Shares

October 2, 2026 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Insider Kevin Mcculloch Sells 15,000 Shares of Stock

October 2, 2026 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Insider Sells 16,666 Shares of Stock

October 2, 2026 | marketbeat.com

Update: Market Chatter: Lundbeck Said to Explore Potential Xeris Biopharma Acquisition

September 30, 2026 | finance.yahoo.com

Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells $250,000.00 in Stock

September 30, 2026 | insidertrades.com

Lundbeck approaches Xeris Biopharma over potential takeover, Bloomberg reports

September 29, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DRUG, TRLV, XERS, and TRVI Company Descriptions

Bright Minds Biosciences NASDAQ:DRUG

$54.02 +2.93 (+5.73%)

Closing price 04:00 PM Eastern

Extended Trading

$55.42 +1.40 (+2.60%)

As of 07:30 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Trulieve Cannabis NYSE:TRLV

$10.66 -0.17 (-1.52%)

Closing price 03:59 PM Eastern

Extended Trading

$10.60 -0.05 (-0.52%)

As of 07:30 PM Eastern

Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida.

Trevi Therapeutics NASDAQ:TRVI

$13.35 +0.84 (+6.71%)

Closing price 04:00 PM Eastern

Extended Trading

$13.88 +0.54 (+4.01%)

As of 07:30 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Xeris Biopharma NASDAQ:XERS

$10.45 +0.24 (+2.35%)

Closing price 04:00 PM Eastern

Extended Trading

$10.52 +0.07 (+0.67%)

As of 07:30 PM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DRUG, TRLV, XERS, and TRVI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DRUG, TRLV, XERS, and TRVI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DRUG, TRLV, XERS, and TRVI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DRUG, TRLV, XERS, and TRVI Company Descriptions

Bright Minds Biosciences NASDAQ:DRUG

Trulieve Cannabis NYSE:TRLV

Trevi Therapeutics NASDAQ:TRVI

Xeris Biopharma NASDAQ:XERS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DRUG, TRLV, XERS, and TRVI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DRUG, TRLV, XERS, and TRVI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DRUG, TRLV, XERS, and TRVI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DRUG, TRLV, XERS, and TRVI Company Descriptions

Bright Minds Biosciences NASDAQ:DRUG

Trulieve Cannabis NYSE:TRLV

Trevi Therapeutics NASDAQ:TRVI

Xeris Biopharma NASDAQ:XERS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools